Navigation Links
MonoSol Rx Appoints Theodore Clemente Vice President Business Development
Date:7/23/2009

WARREN, N.J., July 23 /PRNewswire/ -- MonoSol Rx, the developers of PharmFilm((R)) technology and a drug delivery company specializing in dissolving thin film pharmaceutical products, today announced the appointment of Theodore "Ted" Clemente, Jr. as Vice President, Business Development. Mr. Clemente will report to Keith J. Kendall, Executive Vice President and CFO.

Mr. Kendall stated, "We are pleased to welcome Ted to MonoSol Rx and look forward to benefiting from his expertise as we continue to identify and secure opportunities that leverage the unique attributes of our PharmFilm((R)) technology. Through our strategic partnerships and recent NDA submission for ondansetron orally dissolving thin film, we have validated our thin film platform and its potential to develop new, highly differentiated drug compounds that offer improved compliance, convenience and efficacy. Ted's knowledge of the pharmaceutical industry, and in particular the pressures that companies now face in trying to account for generic encroachment and pending exclusivity losses, will be instrumental as we extend our development pipeline and target additional partnership arrangements."

Prior to joining MonoSol Rx, Mr. Clemente spent the past 12 years with Novartis Consumer Health, Inc. where he most recently served as the Company's Director, Global Business Development and Licensing. While at Novartis Consumer Health, Mr. Clemente built an extensive track record identifying, negotiating and licensing a variety of drug and technology platforms. Among his numerous accomplishments, Mr. Clemente successfully led negotiations for Novartis Consumer Health to acquire exclusive U.S. rights for over-the-counter Prevacid and was responsible for closing the Company's licensing and supply agreement for Triaminic.

A 30-year veteran of the pharmaceutical industry, Mr. Clemente has also held product development and managerial positions with Ciba Self-Medication, Inc., Hoechst-Roussell Pharmaceuticals and Bristol-Myers Products. Mr. Clemente is a graduate of Rutgers College of Pharmacy, Rutgers University.

About MonoSol Rx

MonoSol Rx is a specialty pharmaceutical company leveraging its proprietary PharmFilm(R) technology to deliver drugs in quick dissolving films. PharmFilm(R) is designed to benefit patients by improving the convenience, efficacy, and compliance of new and currently marketed drugs. The Company's leadership in thin film drug delivery is supported by strong intellectual property, a portfolio of commercialized over-the-counter (OTC) drug products, and a development pipeline of prescription formulations based on PharmFilm(R) technology. With a vertically integrated development and production infrastructure, MonoSol Rx has the capacity to manufacture OTC drug products for near-term revenues that fund prescription product development programs that will generate long-term value.

The Company's commercialization strategy for all PharmFilm(R) products is to partner with the innovator, other specialty pharma or leading consumer products companies that can sell-in and manage product sales and marketing. For existing and future partners, PharmFilm(R) formulations represent revenue-life cycle extensions for products with patent lives that have expired or are approaching expiration. PharmFilm(R) is also a tool to help sales and marketing partners differentiate in competitive markets while offering unique advantages over drugs dosed by traditional tablets, capsules and orally disintegrating tablets (ODTs).

    The Ruth Group                        Contact:
    Jason Rando (media)                   MonoSol Rx
    (646) 536-7025                        Keith Kendall
    jrando@theruthgroup.com               Chief Financial Officer
    Sara Ephraim Pellegrino (investors)   (732) 564-5000
    (646) 536-7002
    sephraim@theruthgroup.com


'/>"/>
SOURCE MonoSol Rx
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. MonoSol Rx Announces FDA Acceptance of NDA for Ondansetron Orally Dissolving Film Strip
2. MonoSol Rx and Strativa Pharmaceuticals Submit New Drug Application for Ondansetron Orally Dissolving Film Strip
3. MonoSol Rx Granted U.S. Article of Manufacture Patent
4. MonoSol Rx Enters Agreement with Hikma Pharmaceuticals PLC for Thin Film Pharmaceutical Products in the Middle East
5. MonoSol Rx Successfully Completes Pivotal Bioequivalence Studies for Ondansetron Thin Film NDA
6. MonoSol Rx to Present at the 20th Annual Piper Jaffray Health Care Conference
7. Strativa Pharmaceuticals Acquires Commercialization Rights to Thin Film Formulation of Ondansetron From MonoSol Rx
8. MonoSol Rx Licenses Thin Film Formulation of Ondansetron to Strativa Pharmaceuticals, a Division of Par Pharmaceutical
9. MonoSol Rx Names Vincent Viviani Senior Vice President, Manufacturing and Operations
10. MonoSol Rx Granted US Patent for Thin Film Manufacturing Process
11. WuXi PharmaTech Appoints Dr. Chi-Chung Chan as Vice President of Pharmacology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2016)... (PRWEB) , ... April 30, 2016 , ... Orlando-based Maximized ... as they go for gold in Rio. Under the care of Maximized Living ... golds! , In an unprecedented showing, Maximized Living is sending the largest contingent of ...
(Date:4/29/2016)... Waltham, MA (PRWEB) , ... April 29, 2016 ... ... 1st, the Two Ten Footwear Foundation, the national charitable foundation serving the footwear ... activities. With 8,000 volunteers representing more than 130 companies across 23 states during ...
(Date:4/29/2016)... ... April 29, 2016 , ... On Tuesday, April 26, 2016 members ... celebrated the signature of Gov. Nathan Deal on SB 258, the “Rural Health Care ... Cumming), offers a 70% tax credit to individuals and corporations which donate directly to ...
(Date:4/29/2016)... , ... April 29, 2016 , ... Conditions were ideal ... Cove Island Park on Sunday, with sunny skies, a light breeze and temperatures in ... $33,000. , The 5k Run and Walk and 1-mile walk were held ...
(Date:4/29/2016)... ... April 29, 2016 , ... The ... the $30,000 Perlman Grand Prize of the 2016 Wharton Business Plan Competition ... Michelson People’s Choice Award, and the Committee Award for Most ‘Wow Factor,’ making ...
Breaking Medicine News(10 mins):
(Date:4/29/2016)... , April 29, 2016 /PRNewswire/ ... Contamine, Directeur Financier Sanofi, ... santé, publie ses résultats pour le ... du Groupe, Jérôme Contamine, commente les ... et les perspectives pour le reste ...
(Date:4/28/2016)... YORK , April 28, 2016  While ... notably complement the company,s valve repair and stent ... move also places Abbott more firmly into patient ... of the fastest growing device areas, with double-digit ... its recent report,  Advanced Remote Patient Monitoring ...
(Date:4/28/2016)... April 28, 2016  The blood testing market in ... according to Kalorama Information and The Freedonia Group in ... nucleic acid testing.  The healthcare research firm said that ... developing blood collection stations and in improving testing at ... Information,s report, Blood Testing Market in China ...
Breaking Medicine Technology: